Germany Skin Cancer Diagnostics Market Forecast 2023-2030

The Germany skin cancer diagnostics market is estimated to accelerate with a 7.48% CAGR during the estimation period 2023-2030. The market growth is propelled by rising melanoma incidence, mandatory skin cancer screening, and substantial healthcare expenditure.

MARKET INSIGHTS

Data from the cancer registries of the Saarland and Schleswig-Holstein federal states in Germany underscore the rising incidence and mortality trends associated with skin cancer in the country. In 2019, malignant melanoma, a particularly aggressive skin tumor responsible for over 90% of skin cancer-related deaths, was diagnosed in approximately 22,411 individuals, with a roughly equal distribution between men and women.

Since 2008, Germany has instituted mandatory skin cancer screening by an extensive network of healthcare professionals, including dermatologists, general practitioners, and internists. Despite these efforts, the incidence of malignant melanoma has seen a consistent rise over recent decades, particularly in Bavaria. This trend may be attributed to increased life expectancy and a shift in recreational habits leading to heightened UV exposure.

The rising cost of developing new cancer drugs, with pre-launch R&D costs for anticancer drugs ranging from $944 million to $5.4 billion, significantly contributes to high drug acquisition costs. Given the increasing incidence of skin cancer, the established statutory skin cancer screening mechanism, and significant healthcare expenditure, the Germany skin cancer diagnostic market is poised for continued growth and evolution.

COMPETITIVE INSIGHTS

Leading market players operating cover: NeraCare GmbH, AMLo Biosciences Ltd, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 51872

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. INCREASING PREVALENCE OF SKIN CANCER
- 3.1.2. GROWING AWARENESS ABOUT SKIN CANCER DIAGNOSIS & TREATMENT
- 3.1.3. TECHNOLOGICAL ADVANCEMENTS IN SKIN CANCER DIAGNOSTIC PRODUCTS
3.2. KEY RESTRAINTS
- 3.2.1. HIGH COSTS ASSOCIATED WITH SKIN CANCER TREATMENTS
- 3.2.2. STRINGENT REGULATORY FRAMEWORK
- 3.2.3. LACK OF SKILLED MEDICAL PROFESSIONALS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
4.2. PESTLE ANALYSIS
- 4.2.1. POLITICAL
- 4.2.2. ECONOMICAL
- 4.2.3. SOCIAL
- 4.2.4. TECHNOLOGICAL
- 4.2.5. LEGAL
- 4.2.6. ENVIRONMENTAL
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. VALUE CHAIN ANALYSIS
- 4.4.1. RESEARCH AND DEVELOPMENT
- 4.4.2. MANUFACTURING
- 4.4.3. MARKETING AND SALES
- 4.4.4. DISTRIBUTION AND LOGISTICS
- 4.4.5. TRAINING AND SUPPORT

5. MARKET BY TYPE

5.1. MELANOMA
5.2. NON-MELANOMA

6. MARKET BY GENDER

6.1. MALE
6.2. FEMALE

7. MARKET BY SCREENING TYPE

7.1. SKIN BIOPSY
7.2. DERMATOSCOPY
7.3. LYMPH NODE
7.4. BIOPSY IMAGING TESTS
7.5. BLOOD TESTS

8. COMPETITIVE LANDSCAPE

8.1. KEY STRATEGIC DEVELOPMENTS
- 8.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
- 8.1.2. PARTNERSHIPS & AGREEMENTS
8.2. COMPANY PROFILES
- 8.2.1. BIOMERIEUX SA
- 8.2.2. F. HOFFMANN-LA ROCHE LTD
- 8.2.3. FOTOFINDER
- 8.2.4. NERACARE GMBH
- 8.2.5. SKYLINEDX BV

Product Code: 51872

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - SKIN CANCER DIAGNOSTICS
TABLE 2: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2023-2030 (IN $ MILLION)
TABLE 4: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, FORECAST YEARS, 2023-2030 (IN $ MILLION)
TABLE 6: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, FORECAST YEARS, 2023-2030 (IN $ MILLION)
TABLE 8: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 9: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: VALUE CHAIN ANALYSIS
FIGURE 4: GERMANY SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
FIGURE 5: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY MELANOMA, 2023-2030 (IN $ MILLION)
FIGURE 6: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY NON-MELANOMA, 2023-2030 (IN $ MILLION)
FIGURE 7: GERMANY SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY GENDER, IN 2022
FIGURE 8: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY MALE, 2023-2030 (IN $ MILLION)
FIGURE 9: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY FEMALE, 2023-2030 (IN $ MILLION)
FIGURE 10: GERMANY SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY SCREENING TYPE, IN 2022
FIGURE 11: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY SKIN BIOPSY, 2023-2030 (IN $ MILLION)
FIGURE 12: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY DERMATOSCOPY, 2023-2030 (IN $ MILLION)
FIGURE 13: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY LYMPH NODE, 2023-2030 (IN $ MILLION)
FIGURE 14: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY BIOPSY IMAGING TESTS, 2023-2030 (IN $ MILLION)
FIGURE 15: GERMANY SKIN CANCER DIAGNOSTICS MARKET, BY BLOOD TESTS, 2023-2030 (IN $ MILLION)